[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fi4mlfy_YQw4I9teEafEAdBgcWLJsyOJXhD9UyWB4G2s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"University of Campania Luigi Vanvitelli",[4],171,false,24,7,59075,9,120,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Heart Failure",8,{"name":18,"count":19},"Atrial Fibrillation",5,{"name":21,"count":22},"Obesity",4,{"name":24,"count":22},"Type 2 Diabetes",{"name":26,"count":22},"Type 2 Diabetes Mellitus",{"name":28,"count":22},"Diabetes Mellitus",{"name":30,"count":31},"Diabetes Mellitus, Type 2",3,{"name":33,"count":31},"Fetal Conditions",[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05312398","CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","2026-08-15","Cetuximab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06718452","Tinnitus and Treatment With umPEA-LUT","2026-10-31","umPEALUT + Rutin + 5 hTp",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03463564","Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","2026-12","Insulin injections",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07389265","Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","2030-10","Erbitux",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,87,122,148,166,184,224,242,260,284,327,365,393,443,478,496,514,532,550,568,586,604,622,640,658,676,694,712,730,748,775,793,819,849,867,885,903,921,939,957,983,1001,1026,1049,1067,1093,1111,1139,1157,1175,1200,1225,1243,1268,1293,1316,1341,1365,1390,1421,1439,1461,1486,1511,1538,1556,1582,1607,1625,1643,1667,1710,1747,1774,1800,1824,1849,1867,1893,1920,1938],{"intervention":49,"totalTrials":64,"cells":65},1,{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":73,"PHASE4":75,"NA":85},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[],{"trials":74,"activeCount":68},[],{"trials":76,"activeCount":64,"soonestReadout":48},[77],{"nctId":46,"briefTitle":47,"status":78,"phases":79,"primaryCompletion":48,"completion":48,"start":80,"enrollment":81,"conditions":82,"interventions":84},"RECRUITING",[60],"2016-01",150,[83],"Type 1 Diabetes Mellitus",[49],{"trials":86,"activeCount":68},[],{"intervention":88,"totalTrials":89,"cells":90},"FOLFIRI",2,{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":107,"PHASE4":118,"NA":120},{"trials":92,"activeCount":68},[],{"trials":94,"activeCount":68},[],{"trials":96,"activeCount":64,"soonestReadout":38},[97],{"nctId":36,"briefTitle":37,"status":98,"phases":99,"primaryCompletion":38,"completion":38,"start":100,"enrollment":101,"conditions":102,"interventions":104},"ACTIVE_NOT_RECRUITING",[58],"2021-07-15",219,[103],"Metastatic Colorectal Adenocarcinoma",[39,88,105,106],"FOLFOX regimen","Irinotecan",{"trials":108,"activeCount":64,"soonestReadout":53},[109],{"nctId":51,"briefTitle":52,"status":78,"phases":110,"primaryCompletion":53,"completion":53,"start":111,"enrollment":112,"conditions":113,"interventions":115},[59],"2025-10-01",480,[114],"Metastatic Colorectal Cancer (mCRC)",[54,116,117,88],"Bevacizumab","FOLFOX",{"trials":119,"activeCount":68},[],{"trials":121,"activeCount":68},[],{"intervention":116,"totalTrials":89,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":136,"NA":146},{"trials":125,"activeCount":68},[],{"trials":127,"activeCount":68},[],{"trials":129,"activeCount":68},[],{"trials":131,"activeCount":64,"soonestReadout":53},[132],{"nctId":51,"briefTitle":52,"status":78,"phases":133,"primaryCompletion":53,"completion":53,"start":111,"enrollment":112,"conditions":134,"interventions":135},[59],[114],[54,116,117,88],{"trials":137,"activeCount":68},[138],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"conditions":143,"interventions":145},"NCT01025934","Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy","COMPLETED",[60],[144],"Proliferative Diabetic Retinopathy",[116],{"trials":147,"activeCount":68},[],{"intervention":54,"totalTrials":64,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":162,"NA":164},{"trials":151,"activeCount":68},[],{"trials":153,"activeCount":68},[],{"trials":155,"activeCount":68},[],{"trials":157,"activeCount":64,"soonestReadout":53},[158],{"nctId":51,"briefTitle":52,"status":78,"phases":159,"primaryCompletion":53,"completion":53,"start":111,"enrollment":112,"conditions":160,"interventions":161},[59],[114],[54,116,117,88],{"trials":163,"activeCount":68},[],{"trials":165,"activeCount":68},[],{"intervention":117,"totalTrials":64,"cells":167},{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":180,"NA":182},{"trials":169,"activeCount":68},[],{"trials":171,"activeCount":68},[],{"trials":173,"activeCount":68},[],{"trials":175,"activeCount":64,"soonestReadout":53},[176],{"nctId":51,"briefTitle":52,"status":78,"phases":177,"primaryCompletion":53,"completion":53,"start":111,"enrollment":112,"conditions":178,"interventions":179},[59],[114],[54,116,117,88],{"trials":181,"activeCount":68},[],{"trials":183,"activeCount":68},[],{"intervention":39,"totalTrials":31,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":187,"activeCount":68},[],{"trials":189,"activeCount":68},[],{"trials":191,"activeCount":64,"soonestReadout":38},[192,204,214],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT05291156","CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy","UNKNOWN",[58],"2025-07-01","2022-07-21",173,[201],"Metastatic Colorectal Cancer",[39,203],"Avelumab",{"nctId":205,"briefTitle":206,"status":141,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT04561336","Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer",[58],"2021-11-14","2018-08-10",77,[201,212],"RAS Wild Type",[203,39],{"nctId":36,"briefTitle":37,"status":98,"phases":215,"primaryCompletion":38,"completion":38,"start":100,"enrollment":101,"conditions":216,"interventions":217},[58],[103],[39,88,105,106],{"trials":219,"activeCount":68},[],{"trials":221,"activeCount":68},[],{"trials":223,"activeCount":68},[],{"intervention":105,"totalTrials":64,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":236,"PHASE4":238,"NA":240},{"trials":227,"activeCount":68},[],{"trials":229,"activeCount":68},[],{"trials":231,"activeCount":64,"soonestReadout":38},[232],{"nctId":36,"briefTitle":37,"status":98,"phases":233,"primaryCompletion":38,"completion":38,"start":100,"enrollment":101,"conditions":234,"interventions":235},[58],[103],[39,88,105,106],{"trials":237,"activeCount":68},[],{"trials":239,"activeCount":68},[],{"trials":241,"activeCount":68},[],{"intervention":106,"totalTrials":64,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":254,"PHASE4":256,"NA":258},{"trials":245,"activeCount":68},[],{"trials":247,"activeCount":68},[],{"trials":249,"activeCount":64,"soonestReadout":38},[250],{"nctId":36,"briefTitle":37,"status":98,"phases":251,"primaryCompletion":38,"completion":38,"start":100,"enrollment":101,"conditions":252,"interventions":253},[58],[103],[39,88,105,106],{"trials":255,"activeCount":68},[],{"trials":257,"activeCount":68},[],{"trials":259,"activeCount":68},[],{"intervention":44,"totalTrials":64,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":272},{"trials":263,"activeCount":68},[],{"trials":265,"activeCount":68},[],{"trials":267,"activeCount":68},[],{"trials":269,"activeCount":68},[],{"trials":271,"activeCount":68},[],{"trials":273,"activeCount":64,"soonestReadout":43},[274],{"nctId":41,"briefTitle":42,"status":275,"phases":276,"primaryCompletion":43,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":283},"NOT_YET_RECRUITING",[61],"2026-12-31","2026-04-20",100,[281,282],"Tinnitus","Neuroinflammation",[44],{"intervention":285,"totalTrials":31,"cells":286},"Ivabradine",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":325},{"trials":288,"activeCount":68},[],{"trials":290,"activeCount":68},[],{"trials":292,"activeCount":68},[],{"trials":294,"activeCount":68},[],{"trials":296,"activeCount":68},[297,310,318],{"nctId":298,"briefTitle":299,"status":195,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":308},"NCT01425164","Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol",[60],"2012-06","2011-01",220,[305,306,307],"Coronary Heart Disease","Angina","Hemodialysis",[285,309],"Carvedilol",{"nctId":311,"briefTitle":312,"status":141,"phases":313,"primaryCompletion":302,"completion":314,"start":315,"enrollment":81,"conditions":316,"interventions":317},"NCT01373619","Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine",[60],"2012-01","2010-01",[15],[285],{"nctId":319,"briefTitle":320,"status":195,"phases":321,"primaryCompletion":302,"start":315,"enrollment":279,"conditions":322,"interventions":324},"NCT01364077","Ivabradine in Hemodialysed Patients With Increased Heart Rate",[60],[323],"High Heart Rate",[285],{"trials":326,"activeCount":68},[],{"intervention":328,"totalTrials":89,"cells":329},"vildagliptin",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":363},{"trials":331,"activeCount":68},[],{"trials":333,"activeCount":68},[],{"trials":335,"activeCount":68},[],{"trials":337,"activeCount":68},[],{"trials":339,"activeCount":68},[340,349],{"nctId":341,"briefTitle":342,"status":141,"phases":343,"primaryCompletion":80,"completion":80,"start":344,"enrollment":345,"conditions":346,"interventions":348},"NCT01472432","DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes",[60],"2011-05",106,[347],"Chronic Foot Ulcers",[328],{"nctId":350,"briefTitle":351,"status":195,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":358},"NCT02142309","Glycemic Durability After Metformin Failure",[60],"2015-10","2017-01","2005-10",450,[24],[359,360,361,362],"Glimepiride","Vildagliptin","Pioglitazone","Canagliflozin",{"trials":364,"activeCount":68},[],{"intervention":361,"totalTrials":89,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":391},{"trials":368,"activeCount":68},[],{"trials":370,"activeCount":68},[],{"trials":372,"activeCount":68},[],{"trials":374,"activeCount":68},[],{"trials":376,"activeCount":68},[377,381],{"nctId":350,"briefTitle":351,"status":195,"phases":378,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":379,"interventions":380},[60],[24],[359,360,361,362],{"nctId":382,"briefTitle":383,"status":141,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":81,"conditions":388,"interventions":389},"NCT00815399","Pioglitazone Versus Metformin in Type 2 Diabetes",[60],"2015-03","2015-04","2007-10",[24],[361,390],"Metformin",{"trials":392,"activeCount":68},[],{"intervention":394,"totalTrials":89,"cells":395},"furosemide",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":441},{"trials":397,"activeCount":68},[],{"trials":399,"activeCount":68},[],{"trials":401,"activeCount":68},[],{"trials":403,"activeCount":68},[],{"trials":405,"activeCount":68},[406,429],{"nctId":407,"briefTitle":408,"status":141,"phases":409,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":413,"interventions":415},"NCT00535925","Nephropathy In Type 2 Diabetes and Cardio-renal Events",[60],"2011-12","2019-05",850,[414],"Diabetic Nephropathy",[416,417,418,419,394,420,421,422,423,424,425,426,427,428],"SoC therapy","irbesartan","ramipril","hydrochlorothiazide","amlodipine","atenolol","doxazosin","clonidine","insulin","simvastatin","fibrate","erythropoietin","aspirin",{"nctId":430,"briefTitle":431,"status":141,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT00478543","Loop Diuretics in Chronic Kidney Disease",[60],"2008-05","2008-07","2005-09",40,[438],"Chronic Kidney Disease",[440],"Furosemide",{"trials":442,"activeCount":68},[],{"intervention":444,"totalTrials":89,"cells":445},"aliskiren",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":476},{"trials":447,"activeCount":68},[],{"trials":449,"activeCount":68},[],{"trials":451,"activeCount":68},[],{"trials":453,"activeCount":68},[],{"trials":455,"activeCount":68},[456,467],{"nctId":457,"briefTitle":458,"status":195,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":466},"NCT01635387","RAAS Inhibitor Drugs in Dialysis Patients",[60],"2012-09","2010-02",350,[464,465],"Hypertension","End Stage Renal Disease",[444],{"nctId":468,"briefTitle":469,"status":195,"phases":470,"primaryCompletion":460,"completion":460,"start":471,"enrollment":462,"conditions":472,"interventions":474},"NCT01394770","Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients",[60],"2009-09",[464,473],"Dialysis",[475],"Aliskiren",{"trials":477,"activeCount":68},[],{"intervention":359,"totalTrials":64,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":68},[],{"trials":483,"activeCount":68},[],{"trials":485,"activeCount":68},[],{"trials":487,"activeCount":68},[],{"trials":489,"activeCount":68},[490],{"nctId":350,"briefTitle":351,"status":195,"phases":491,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":492,"interventions":493},[60],[24],[359,360,361,362],{"trials":495,"activeCount":68},[],{"intervention":362,"totalTrials":64,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":499,"activeCount":68},[],{"trials":501,"activeCount":68},[],{"trials":503,"activeCount":68},[],{"trials":505,"activeCount":68},[],{"trials":507,"activeCount":68},[508],{"nctId":350,"briefTitle":351,"status":195,"phases":509,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":510,"interventions":511},[60],[24],[359,360,361,362],{"trials":513,"activeCount":68},[],{"intervention":309,"totalTrials":64,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":530},{"trials":517,"activeCount":68},[],{"trials":519,"activeCount":68},[],{"trials":521,"activeCount":68},[],{"trials":523,"activeCount":68},[],{"trials":525,"activeCount":68},[526],{"nctId":298,"briefTitle":299,"status":195,"phases":527,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":528,"interventions":529},[60],[305,306,307],[285,309],{"trials":531,"activeCount":68},[],{"intervention":416,"totalTrials":64,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":548},{"trials":535,"activeCount":68},[],{"trials":537,"activeCount":68},[],{"trials":539,"activeCount":68},[],{"trials":541,"activeCount":68},[],{"trials":543,"activeCount":68},[544],{"nctId":407,"briefTitle":408,"status":141,"phases":545,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":546,"interventions":547},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":549,"activeCount":68},[],{"intervention":417,"totalTrials":64,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":566},{"trials":553,"activeCount":68},[],{"trials":555,"activeCount":68},[],{"trials":557,"activeCount":68},[],{"trials":559,"activeCount":68},[],{"trials":561,"activeCount":68},[562],{"nctId":407,"briefTitle":408,"status":141,"phases":563,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":564,"interventions":565},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":567,"activeCount":68},[],{"intervention":418,"totalTrials":64,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":584},{"trials":571,"activeCount":68},[],{"trials":573,"activeCount":68},[],{"trials":575,"activeCount":68},[],{"trials":577,"activeCount":68},[],{"trials":579,"activeCount":68},[580],{"nctId":407,"briefTitle":408,"status":141,"phases":581,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":582,"interventions":583},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":585,"activeCount":68},[],{"intervention":419,"totalTrials":64,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":602},{"trials":589,"activeCount":68},[],{"trials":591,"activeCount":68},[],{"trials":593,"activeCount":68},[],{"trials":595,"activeCount":68},[],{"trials":597,"activeCount":68},[598],{"nctId":407,"briefTitle":408,"status":141,"phases":599,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":600,"interventions":601},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":603,"activeCount":68},[],{"intervention":420,"totalTrials":64,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":620},{"trials":607,"activeCount":68},[],{"trials":609,"activeCount":68},[],{"trials":611,"activeCount":68},[],{"trials":613,"activeCount":68},[],{"trials":615,"activeCount":68},[616],{"nctId":407,"briefTitle":408,"status":141,"phases":617,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":618,"interventions":619},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":621,"activeCount":68},[],{"intervention":421,"totalTrials":64,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":638},{"trials":625,"activeCount":68},[],{"trials":627,"activeCount":68},[],{"trials":629,"activeCount":68},[],{"trials":631,"activeCount":68},[],{"trials":633,"activeCount":68},[634],{"nctId":407,"briefTitle":408,"status":141,"phases":635,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":636,"interventions":637},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":639,"activeCount":68},[],{"intervention":422,"totalTrials":64,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":656},{"trials":643,"activeCount":68},[],{"trials":645,"activeCount":68},[],{"trials":647,"activeCount":68},[],{"trials":649,"activeCount":68},[],{"trials":651,"activeCount":68},[652],{"nctId":407,"briefTitle":408,"status":141,"phases":653,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":654,"interventions":655},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":657,"activeCount":68},[],{"intervention":423,"totalTrials":64,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":661,"activeCount":68},[],{"trials":663,"activeCount":68},[],{"trials":665,"activeCount":68},[],{"trials":667,"activeCount":68},[],{"trials":669,"activeCount":68},[670],{"nctId":407,"briefTitle":408,"status":141,"phases":671,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":672,"interventions":673},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":675,"activeCount":68},[],{"intervention":425,"totalTrials":64,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":692},{"trials":679,"activeCount":68},[],{"trials":681,"activeCount":68},[],{"trials":683,"activeCount":68},[],{"trials":685,"activeCount":68},[],{"trials":687,"activeCount":68},[688],{"nctId":407,"briefTitle":408,"status":141,"phases":689,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":690,"interventions":691},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":693,"activeCount":68},[],{"intervention":426,"totalTrials":64,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":710},{"trials":697,"activeCount":68},[],{"trials":699,"activeCount":68},[],{"trials":701,"activeCount":68},[],{"trials":703,"activeCount":68},[],{"trials":705,"activeCount":68},[706],{"nctId":407,"briefTitle":408,"status":141,"phases":707,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":708,"interventions":709},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":711,"activeCount":68},[],{"intervention":427,"totalTrials":64,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":728},{"trials":715,"activeCount":68},[],{"trials":717,"activeCount":68},[],{"trials":719,"activeCount":68},[],{"trials":721,"activeCount":68},[],{"trials":723,"activeCount":68},[724],{"nctId":407,"briefTitle":408,"status":141,"phases":725,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":726,"interventions":727},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":729,"activeCount":68},[],{"intervention":428,"totalTrials":64,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":746},{"trials":733,"activeCount":68},[],{"trials":735,"activeCount":68},[],{"trials":737,"activeCount":68},[],{"trials":739,"activeCount":68},[],{"trials":741,"activeCount":68},[742],{"nctId":407,"briefTitle":408,"status":141,"phases":743,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":744,"interventions":745},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"trials":747,"activeCount":68},[],{"intervention":749,"totalTrials":64,"cells":750},"Fosfomycin 3 g",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":773},{"trials":752,"activeCount":68},[],{"trials":754,"activeCount":68},[],{"trials":756,"activeCount":68},[],{"trials":758,"activeCount":68},[],{"trials":760,"activeCount":68},[761],{"nctId":762,"briefTitle":763,"status":141,"phases":764,"primaryCompletion":765,"completion":766,"start":767,"enrollment":768,"conditions":769,"interventions":771},"NCT06659016","Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulphate and D-Mannose to Avoid Symptoms and Prevents Recurrence in Women With Recurrent Urinary Tract Infections",[60],"2024-02-10","2024-09-30","2023-02-01",148,[770],"Urinary Tract Infection (Diagnosis)",[749,772],"Combination of dietary supplement and fosfomycin",{"trials":774,"activeCount":68},[],{"intervention":772,"totalTrials":64,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":791},{"trials":778,"activeCount":68},[],{"trials":780,"activeCount":68},[],{"trials":782,"activeCount":68},[],{"trials":784,"activeCount":68},[],{"trials":786,"activeCount":68},[787],{"nctId":762,"briefTitle":763,"status":141,"phases":788,"primaryCompletion":765,"completion":766,"start":767,"enrollment":768,"conditions":789,"interventions":790},[60],[770],[749,772],{"trials":792,"activeCount":68},[],{"intervention":794,"totalTrials":64,"cells":795},"Ingenol mebutate",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":817},{"trials":797,"activeCount":68},[],{"trials":799,"activeCount":68},[],{"trials":801,"activeCount":68},[],{"trials":803,"activeCount":68},[],{"trials":805,"activeCount":68},[806],{"nctId":807,"briefTitle":808,"status":141,"phases":809,"primaryCompletion":810,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":816},"NCT02990221","Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy",[60],"2018-04-30","2018-07-30","2017-04-12",50,[815],"Actinic Keratosis",[794],{"trials":818,"activeCount":68},[],{"intervention":820,"totalTrials":64,"cells":821},"IDegLira",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":847},{"trials":823,"activeCount":68},[],{"trials":825,"activeCount":68},[],{"trials":827,"activeCount":68},[],{"trials":829,"activeCount":68},[],{"trials":831,"activeCount":68},[832],{"nctId":833,"briefTitle":834,"status":141,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT04196231","Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)",[60],"2020-09-30","2020-10-20","2019-11-27",258,[24],[820,842,843,844,845,846],"IGlarLixi","Insulin\u002FCanaglifozin","Insulin\u002FDapaglifozin","Insulin\u002FEmpaglifozin","Basal Bolus",{"trials":848,"activeCount":68},[],{"intervention":842,"totalTrials":64,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":865},{"trials":852,"activeCount":68},[],{"trials":854,"activeCount":68},[],{"trials":856,"activeCount":68},[],{"trials":858,"activeCount":68},[],{"trials":860,"activeCount":68},[861],{"nctId":833,"briefTitle":834,"status":141,"phases":862,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":863,"interventions":864},[60],[24],[820,842,843,844,845,846],{"trials":866,"activeCount":68},[],{"intervention":843,"totalTrials":64,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":883},{"trials":870,"activeCount":68},[],{"trials":872,"activeCount":68},[],{"trials":874,"activeCount":68},[],{"trials":876,"activeCount":68},[],{"trials":878,"activeCount":68},[879],{"nctId":833,"briefTitle":834,"status":141,"phases":880,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":881,"interventions":882},[60],[24],[820,842,843,844,845,846],{"trials":884,"activeCount":68},[],{"intervention":844,"totalTrials":64,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":895,"NA":901},{"trials":888,"activeCount":68},[],{"trials":890,"activeCount":68},[],{"trials":892,"activeCount":68},[],{"trials":894,"activeCount":68},[],{"trials":896,"activeCount":68},[897],{"nctId":833,"briefTitle":834,"status":141,"phases":898,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":899,"interventions":900},[60],[24],[820,842,843,844,845,846],{"trials":902,"activeCount":68},[],{"intervention":845,"totalTrials":64,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":919},{"trials":906,"activeCount":68},[],{"trials":908,"activeCount":68},[],{"trials":910,"activeCount":68},[],{"trials":912,"activeCount":68},[],{"trials":914,"activeCount":68},[915],{"nctId":833,"briefTitle":834,"status":141,"phases":916,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":917,"interventions":918},[60],[24],[820,842,843,844,845,846],{"trials":920,"activeCount":68},[],{"intervention":846,"totalTrials":64,"cells":922},{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":937},{"trials":924,"activeCount":68},[],{"trials":926,"activeCount":68},[],{"trials":928,"activeCount":68},[],{"trials":930,"activeCount":68},[],{"trials":932,"activeCount":68},[933],{"nctId":833,"briefTitle":834,"status":141,"phases":934,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":935,"interventions":936},[60],[24],[820,842,843,844,845,846],{"trials":938,"activeCount":68},[],{"intervention":390,"totalTrials":64,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":955},{"trials":942,"activeCount":68},[],{"trials":944,"activeCount":68},[],{"trials":946,"activeCount":68},[],{"trials":948,"activeCount":68},[],{"trials":950,"activeCount":68},[951],{"nctId":382,"briefTitle":383,"status":141,"phases":952,"primaryCompletion":385,"completion":386,"start":387,"enrollment":81,"conditions":953,"interventions":954},[60],[24],[361,390],{"trials":956,"activeCount":68},[],{"intervention":958,"totalTrials":64,"cells":959},"NPL insulin",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":981},{"trials":961,"activeCount":68},[],{"trials":963,"activeCount":68},[],{"trials":965,"activeCount":68},[],{"trials":967,"activeCount":68},[],{"trials":969,"activeCount":68},[970],{"nctId":971,"briefTitle":972,"status":141,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":279,"conditions":977,"interventions":979},"NCT00641407","Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes",[60],"2007-12","2008-03","2007-01",[26,978],"Hypoglycemia",[958,980],"Insulin glargine",{"trials":982,"activeCount":68},[],{"intervention":980,"totalTrials":64,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":999},{"trials":986,"activeCount":68},[],{"trials":988,"activeCount":68},[],{"trials":990,"activeCount":68},[],{"trials":992,"activeCount":68},[],{"trials":994,"activeCount":68},[995],{"nctId":971,"briefTitle":972,"status":141,"phases":996,"primaryCompletion":974,"completion":975,"start":976,"enrollment":279,"conditions":997,"interventions":998},[60],[26,978],[958,980],{"trials":1000,"activeCount":68},[],{"intervention":1002,"totalTrials":64,"cells":1003},"stem cells",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1024},{"trials":1005,"activeCount":68},[],{"trials":1007,"activeCount":68},[],{"trials":1009,"activeCount":68},[],{"trials":1011,"activeCount":68},[],{"trials":1013,"activeCount":68},[1014],{"nctId":1015,"briefTitle":1016,"status":195,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":315,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT02871466","Stem Cells Therapy in Advanced Heart Failure",[60],"2022-01","2022-07",30,[1022],"Congestive Heart Failure",[1002],{"trials":1025,"activeCount":68},[],{"intervention":1027,"totalTrials":64,"cells":1028},"lyspro",{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1047},{"trials":1030,"activeCount":68},[],{"trials":1032,"activeCount":68},[],{"trials":1034,"activeCount":68},[],{"trials":1036,"activeCount":68},[],{"trials":1038,"activeCount":68},[1039],{"nctId":1040,"briefTitle":1041,"status":141,"phases":1042,"conditions":1043,"interventions":1045},"NCT00513201","Lyspro Insulin vs Regular Insulin in Cirrhotic Patients",[60],[28,1044],"Cirrhosis",[1027,1046],"regular insulin",{"trials":1048,"activeCount":68},[],{"intervention":1046,"totalTrials":64,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1065},{"trials":1052,"activeCount":68},[],{"trials":1054,"activeCount":68},[],{"trials":1056,"activeCount":68},[],{"trials":1058,"activeCount":68},[],{"trials":1060,"activeCount":68},[1061],{"nctId":1040,"briefTitle":1041,"status":141,"phases":1062,"conditions":1063,"interventions":1064},[60],[28,1044],[1027,1046],{"trials":1066,"activeCount":68},[],{"intervention":1068,"totalTrials":64,"cells":1069},"alpha-lipoic acid",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1091},{"trials":1071,"activeCount":68},[],{"trials":1073,"activeCount":68},[],{"trials":1075,"activeCount":68},[],{"trials":1077,"activeCount":68},[],{"trials":1079,"activeCount":68},[1080],{"nctId":1081,"briefTitle":1082,"status":141,"phases":1083,"primaryCompletion":1084,"completion":80,"start":410,"enrollment":1085,"conditions":1086,"interventions":1089},"NCT01524861","Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy",[60],"2015-12",90,[1087,1088],"Apical Ballooning Syndrome","Nervous System Diseases, Sympathetic",[1068,1090],"L-acetyl carnitine",{"trials":1092,"activeCount":68},[],{"intervention":1090,"totalTrials":64,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1109},{"trials":1096,"activeCount":68},[],{"trials":1098,"activeCount":68},[],{"trials":1100,"activeCount":68},[],{"trials":1102,"activeCount":68},[],{"trials":1104,"activeCount":68},[1105],{"nctId":1081,"briefTitle":1082,"status":141,"phases":1106,"primaryCompletion":1084,"completion":80,"start":410,"enrollment":1085,"conditions":1107,"interventions":1108},[60],[1087,1088],[1068,1090],{"trials":1110,"activeCount":68},[],{"intervention":1112,"totalTrials":64,"cells":1113},"fenofibrate",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1137},{"trials":1115,"activeCount":68},[],{"trials":1117,"activeCount":68},[],{"trials":1119,"activeCount":68},[],{"trials":1121,"activeCount":68},[],{"trials":1123,"activeCount":68},[1124],{"nctId":1125,"briefTitle":1126,"status":195,"phases":1127,"primaryCompletion":353,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1134},"NCT00923676","Treatment of Hyperlipidemia and Sexual Dysfunction",[60],"2016-04","2008-04",300,[1132,1133],"Sexual Dysfunction","Hyperlipidemia",[1112,1135,1136],"Rosuvastatin","fenofibrate + rosuvastatin",{"trials":1138,"activeCount":68},[],{"intervention":1135,"totalTrials":64,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1155},{"trials":1142,"activeCount":68},[],{"trials":1144,"activeCount":68},[],{"trials":1146,"activeCount":68},[],{"trials":1148,"activeCount":68},[],{"trials":1150,"activeCount":68},[1151],{"nctId":1125,"briefTitle":1126,"status":195,"phases":1152,"primaryCompletion":353,"completion":1128,"start":1129,"enrollment":1130,"conditions":1153,"interventions":1154},[60],[1132,1133],[1112,1135,1136],{"trials":1156,"activeCount":68},[],{"intervention":1136,"totalTrials":64,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1173},{"trials":1160,"activeCount":68},[],{"trials":1162,"activeCount":68},[],{"trials":1164,"activeCount":68},[],{"trials":1166,"activeCount":68},[],{"trials":1168,"activeCount":68},[1169],{"nctId":1125,"briefTitle":1126,"status":195,"phases":1170,"primaryCompletion":353,"completion":1128,"start":1129,"enrollment":1130,"conditions":1171,"interventions":1172},[60],[1132,1133],[1112,1135,1136],{"trials":1174,"activeCount":68},[],{"intervention":1176,"totalTrials":64,"cells":1177},"Liraglutide",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1198},{"trials":1179,"activeCount":68},[],{"trials":1181,"activeCount":68},[],{"trials":1183,"activeCount":68},[],{"trials":1185,"activeCount":68},[],{"trials":1187,"activeCount":68},[1188],{"nctId":1189,"briefTitle":1190,"status":141,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1197},"NCT04881110","Liraglutide and Peripheral Artery Disease",[60],"2022-12-31","2021-02-01",60,[24,1196],"Peripheral Arterial Disease",[1176],{"trials":1199,"activeCount":68},[],{"intervention":1201,"totalTrials":64,"cells":1202},"Incretin Effect",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1223},{"trials":1204,"activeCount":68},[],{"trials":1206,"activeCount":68},[],{"trials":1208,"activeCount":68},[],{"trials":1210,"activeCount":68},[],{"trials":1212,"activeCount":68},[1213],{"nctId":1214,"briefTitle":1215,"status":141,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT03282136","SGLT2i and Incretin and CRTd.",[60],"2024-09-01","2017-09-01",500,[26,15],[1201,1222],"SGLT-2 inhibitor",{"trials":1224,"activeCount":68},[],{"intervention":1222,"totalTrials":64,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1241},{"trials":1228,"activeCount":68},[],{"trials":1230,"activeCount":68},[],{"trials":1232,"activeCount":68},[],{"trials":1234,"activeCount":68},[],{"trials":1236,"activeCount":68},[1237],{"nctId":1214,"briefTitle":1215,"status":141,"phases":1238,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1239,"interventions":1240},[60],[26,15],[1201,1222],{"trials":1242,"activeCount":68},[],{"intervention":1244,"totalTrials":64,"cells":1245},"SLGT2",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1266},{"trials":1247,"activeCount":68},[],{"trials":1249,"activeCount":68},[],{"trials":1251,"activeCount":68},[],{"trials":1253,"activeCount":68},[],{"trials":1255,"activeCount":68},[1256],{"nctId":1257,"briefTitle":1258,"status":141,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":279,"conditions":1263,"interventions":1265},"NCT03977116","Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients",[60],"2019-01-01","2019-03-01","2017-01-01",[28,15,1264],"Ventricular Arrythmia",[1244],{"trials":1267,"activeCount":68},[],{"intervention":1269,"totalTrials":64,"cells":1270},"telmisartan",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1279,"NA":1291},{"trials":1272,"activeCount":68},[],{"trials":1274,"activeCount":68},[],{"trials":1276,"activeCount":68},[],{"trials":1278,"activeCount":68},[],{"trials":1280,"activeCount":68},[1281],{"nctId":1282,"briefTitle":1283,"status":141,"phases":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT00490958","Telmisartan in Haemodialysis Patients With Chronic Heart Failure",[60],"2005-06","1999-01",351,[1289],"Heart Failure, Congestive",[1269],{"trials":1292,"activeCount":68},[],{"intervention":1294,"totalTrials":64,"cells":1295},"Eradication therapy",{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1312,"NA":1314},{"trials":1297,"activeCount":68},[],{"trials":1299,"activeCount":68},[],{"trials":1301,"activeCount":68},[],{"trials":1303,"activeCount":68},[1304],{"nctId":1305,"briefTitle":1306,"status":141,"phases":1307,"primaryCompletion":344,"completion":410,"start":302,"enrollment":1308,"conditions":1309,"interventions":1311},"NCT01544517","5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection",[59],180,[1310],"Helicobacter Pylori Infection",[1294],{"trials":1313,"activeCount":68},[],{"trials":1315,"activeCount":68},[],{"intervention":1317,"totalTrials":64,"cells":1318},"Resveratrol nasal spray",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1337,"NA":1339},{"trials":1320,"activeCount":68},[],{"trials":1322,"activeCount":68},[],{"trials":1324,"activeCount":68},[],{"trials":1326,"activeCount":68},[1327],{"nctId":1328,"briefTitle":1329,"status":141,"phases":1330,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":279,"conditions":1334,"interventions":1336},"NCT02130440","Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis",[59],"2013-12","2014-04","2012-11",[1335],"Seasonal Allergic Rhinitis",[1317],{"trials":1338,"activeCount":68},[],{"trials":1340,"activeCount":68},[],{"intervention":1342,"totalTrials":64,"cells":1343},"Bifidobacteria",{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1361,"NA":1363},{"trials":1345,"activeCount":68},[],{"trials":1347,"activeCount":68},[],{"trials":1349,"activeCount":68},[],{"trials":1351,"activeCount":68},[1352],{"nctId":1353,"briefTitle":1354,"status":195,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":436,"conditions":1359,"interventions":1360},"NCT02807064","Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis",[59],"2018-07","2019-07","2016-12",[1335],[1342],{"trials":1362,"activeCount":68},[],{"trials":1364,"activeCount":68},[],{"intervention":1366,"totalTrials":64,"cells":1367},"Reuterin D3 drops",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1386,"NA":1388},{"trials":1369,"activeCount":68},[],{"trials":1371,"activeCount":68},[],{"trials":1373,"activeCount":68},[],{"trials":1375,"activeCount":68},[1376],{"nctId":1377,"briefTitle":1378,"status":141,"phases":1379,"primaryCompletion":1380,"completion":1381,"start":1332,"enrollment":1382,"conditions":1383,"interventions":1385},"NCT02734446","To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children",[59],"2015-02","2016-03",52,[1384],"Asthma",[1366],{"trials":1387,"activeCount":68},[],{"trials":1389,"activeCount":68},[],{"intervention":1391,"totalTrials":64,"cells":1392},"Colistin",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1417,"NA":1419},{"trials":1394,"activeCount":68},[],{"trials":1396,"activeCount":68},[],{"trials":1398,"activeCount":68},[],{"trials":1400,"activeCount":68},[1401],{"nctId":1402,"briefTitle":1403,"status":141,"phases":1404,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1415},"NCT01577862","Colistin and Rifampicin for MDR-Acinetobacter",[59],"2011-08","2011-10","2008-11",210,[1410,1411,1412,1413,1414],"Infection Due to Resistant Bacteria","Pneumonia, Ventilator-Associated","Hospital Acquired Pneumonia","Infection of Bloodstream","Infectious Disease of Abdomen",[1391,1416],"Rifampicin",{"trials":1418,"activeCount":68},[],{"trials":1420,"activeCount":68},[],{"intervention":1416,"totalTrials":64,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1435,"NA":1437},{"trials":1424,"activeCount":68},[],{"trials":1426,"activeCount":68},[],{"trials":1428,"activeCount":68},[],{"trials":1430,"activeCount":68},[1431],{"nctId":1402,"briefTitle":1403,"status":141,"phases":1432,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1433,"interventions":1434},[59],[1410,1411,1412,1413,1414],[1391,1416],{"trials":1436,"activeCount":68},[],{"trials":1438,"activeCount":68},[],{"intervention":203,"totalTrials":89,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1442,"activeCount":68},[],{"trials":1444,"activeCount":68},[],{"trials":1446,"activeCount":68},[1447,1451],{"nctId":193,"briefTitle":194,"status":195,"phases":1448,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":1449,"interventions":1450},[58],[201],[39,203],{"nctId":205,"briefTitle":206,"status":141,"phases":1452,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1453,"interventions":1454},[58],[201,212],[203,39],{"trials":1456,"activeCount":68},[],{"trials":1458,"activeCount":68},[],{"trials":1460,"activeCount":68},[],{"intervention":1462,"totalTrials":64,"cells":1463},"Next Generation Sequencing and Network Analysis",{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1465,"activeCount":68},[],{"trials":1467,"activeCount":68},[],{"trials":1469,"activeCount":68},[1470],{"nctId":1471,"briefTitle":1472,"status":195,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1018,"enrollment":1476,"conditions":1477,"interventions":1479},"NCT04996836","Breast Cancer, Omics, and Precision Medicine",[58],"2022-12","2023-12",200,[1478],"Breast Cancer",[1462],{"trials":1481,"activeCount":68},[],{"trials":1483,"activeCount":68},[],{"trials":1485,"activeCount":68},[],{"intervention":1487,"totalTrials":64,"cells":1488},"Cabozantinib",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1490,"activeCount":68},[],{"trials":1492,"activeCount":68},[],{"trials":1494,"activeCount":68},[1495],{"nctId":1496,"briefTitle":1497,"status":195,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1504},"NCT06171854","caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.",[58],"2024-12-31","2019-09-01",33,[1503],"Refractory Colorectal Adenocarcinoma",[1487],{"trials":1506,"activeCount":68},[],{"trials":1508,"activeCount":68},[],{"trials":1510,"activeCount":68},[],{"intervention":1512,"totalTrials":64,"cells":1513},"Trifluridine Tipiracil",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1515,"activeCount":68},[],{"trials":1517,"activeCount":68},[],{"trials":1519,"activeCount":68},[1520],{"nctId":1521,"briefTitle":1522,"status":141,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1530},"NCT05468892","Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial",[58],"2022-05-31","2022-06-30","2019-10-29",68,[1529],"Metastatic Colon Cancer",[1512,1531],"Panitumumab 20 MG\u002F1 ML Intravenous Solution [VECTIBIX]",{"trials":1533,"activeCount":68},[],{"trials":1535,"activeCount":68},[],{"trials":1537,"activeCount":68},[],{"intervention":1531,"totalTrials":64,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1541,"activeCount":68},[],{"trials":1543,"activeCount":68},[],{"trials":1545,"activeCount":68},[1546],{"nctId":1521,"briefTitle":1522,"status":141,"phases":1547,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":1548,"interventions":1549},[58],[1529],[1512,1531],{"trials":1551,"activeCount":68},[],{"trials":1553,"activeCount":68},[],{"trials":1555,"activeCount":68},[],{"intervention":1557,"totalTrials":64,"cells":1558},"intravitreal",{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1560,"activeCount":68},[],{"trials":1562,"activeCount":68},[1563],{"nctId":1564,"briefTitle":1565,"status":141,"phases":1566,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":19,"conditions":1570,"interventions":1573},"NCT00406250","Intravitreal Bevacizumab in Agioid Streaks",[57],"2008-12","2009-05","2006-11",[1571,1572],"Angioid Streaks","Choroidal Neovascularization",[1557,1557],{"trials":1575,"activeCount":68},[],{"trials":1577,"activeCount":68},[],{"trials":1579,"activeCount":68},[],{"trials":1581,"activeCount":68},[],{"intervention":1583,"totalTrials":64,"cells":1584},"PDT standard fluence, ranibizumab",{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1586,"activeCount":68},[],{"trials":1588,"activeCount":68},[1589],{"nctId":1590,"briefTitle":1591,"status":141,"phases":1592,"primaryCompletion":1593,"completion":1593,"start":301,"enrollment":1194,"conditions":1594,"interventions":1596},"NCT01968486","Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia",[57],"2013-07",[1595],"Myopia, Degenerative",[1583,1597,1598],"PDT reduced fluence, ranibizumab","ranibizumab",{"trials":1600,"activeCount":68},[],{"trials":1602,"activeCount":68},[],{"trials":1604,"activeCount":68},[],{"trials":1606,"activeCount":68},[],{"intervention":1597,"totalTrials":64,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1617,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1610,"activeCount":68},[],{"trials":1612,"activeCount":68},[1613],{"nctId":1590,"briefTitle":1591,"status":141,"phases":1614,"primaryCompletion":1593,"completion":1593,"start":301,"enrollment":1194,"conditions":1615,"interventions":1616},[57],[1595],[1583,1597,1598],{"trials":1618,"activeCount":68},[],{"trials":1620,"activeCount":68},[],{"trials":1622,"activeCount":68},[],{"trials":1624,"activeCount":68},[],{"intervention":1598,"totalTrials":64,"cells":1626},{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1641},{"trials":1628,"activeCount":68},[],{"trials":1630,"activeCount":68},[1631],{"nctId":1590,"briefTitle":1591,"status":141,"phases":1632,"primaryCompletion":1593,"completion":1593,"start":301,"enrollment":1194,"conditions":1633,"interventions":1634},[57],[1595],[1583,1597,1598],{"trials":1636,"activeCount":68},[],{"trials":1638,"activeCount":68},[],{"trials":1640,"activeCount":68},[],{"trials":1642,"activeCount":68},[],{"intervention":1644,"totalTrials":64,"cells":1645},"Combination therapy \"IVB + rf-PDT\"",{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1647,"activeCount":68},[],{"trials":1649,"activeCount":68},[1650],{"nctId":1651,"briefTitle":1652,"status":141,"phases":1653,"primaryCompletion":1567,"completion":1568,"start":1654,"enrollment":1655,"conditions":1656,"interventions":1658},"NCT00802126","Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy",[57],"2007-11",16,[1657],"Myopia",[1644],{"trials":1660,"activeCount":68},[],{"trials":1662,"activeCount":68},[],{"trials":1664,"activeCount":68},[],{"trials":1666,"activeCount":68},[],{"intervention":1668,"totalTrials":31,"cells":1669},"Insulin",{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1697},{"trials":1671,"activeCount":68},[],{"trials":1673,"activeCount":68},[],{"trials":1675,"activeCount":68},[],{"trials":1677,"activeCount":68},[],{"trials":1679,"activeCount":68},[1680,1684],{"nctId":407,"briefTitle":408,"status":141,"phases":1681,"primaryCompletion":410,"completion":411,"start":355,"enrollment":412,"conditions":1682,"interventions":1683},[60],[414],[416,417,418,419,394,420,421,422,423,424,425,426,427,428],{"nctId":1685,"briefTitle":1686,"status":141,"phases":1687,"primaryCompletion":1688,"completion":1689,"start":1690,"enrollment":1691,"conditions":1692,"interventions":1696},"NCT00863629","Tight Glycemic Control Increases Cardiac Stem Cells During Acute Myocardial Infarction",[60],"2008-06","2009-01","2001-01",65,[1693,1694,1695],"Myocardial Infarction","Oxidative Stress","Glycemic Control",[1668],{"trials":1698,"activeCount":68},[1699],{"nctId":1700,"briefTitle":1701,"status":141,"phases":1702,"primaryCompletion":1703,"completion":1704,"start":1705,"enrollment":1476,"conditions":1706,"interventions":1709},"NCT01016509","Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis",[61],"2010-06","2010-12","2009-12",[1707,1708],"Restenosis","Tight Glycemic Control",[1668,1668],{"intervention":1711,"totalTrials":89,"cells":1712},"Incretins",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1734},{"trials":1714,"activeCount":68},[],{"trials":1716,"activeCount":68},[],{"trials":1718,"activeCount":68},[],{"trials":1720,"activeCount":68},[],{"trials":1722,"activeCount":68},[1723],{"nctId":1724,"briefTitle":1725,"status":141,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":81,"conditions":1730,"interventions":1733},"NCT03360981","Epicardial Fat and Clinical Outcomes After Coronary Artery Bypass Grafting in Diabetics vs. Non Diabetics",[60],"2017-11-20","2025-08-20","2017-09-20",[1731,1732],"Diabetes","Coronary Artery Disease",[1711],{"trials":1735,"activeCount":68},[1736],{"nctId":1737,"briefTitle":1738,"status":141,"phases":1739,"primaryCompletion":1218,"completion":1740,"start":1262,"enrollment":1741,"conditions":1742,"interventions":1746},"NCT03312179","STEMI and Incretins Treatment",[],"2017-10-01",900,[1743,1732,1744,1745,1731],"STEMI","Coronary Syndrome","Coronary Arteriosclerosis",[1711],{"intervention":1748,"totalTrials":64,"cells":1749},"Nutraceutical therapy",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1751,"activeCount":68},[],{"trials":1753,"activeCount":68},[],{"trials":1755,"activeCount":68},[],{"trials":1757,"activeCount":68},[],{"trials":1759,"activeCount":68},[],{"trials":1761,"activeCount":68},[1762],{"nctId":1763,"briefTitle":1764,"status":141,"phases":1765,"primaryCompletion":1766,"completion":1767,"start":1768,"enrollment":1769,"conditions":1770,"interventions":1773},"NCT04640324","Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.",[61],"2017-10-17","2018-04-17","2017-01-16",92,[1771,1772],"Non-Alcoholic Fatty Liver Disease","Insulin Resistance",[1748],{"intervention":1775,"totalTrials":64,"cells":1776},"statin Oral Tablet plus PCSK9i",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1778,"activeCount":68},[],{"trials":1780,"activeCount":68},[],{"trials":1782,"activeCount":68},[],{"trials":1784,"activeCount":68},[],{"trials":1786,"activeCount":68},[],{"trials":1788,"activeCount":68},[1789],{"nctId":1790,"briefTitle":1791,"status":141,"phases":1792,"primaryCompletion":1262,"completion":1793,"start":1794,"enrollment":1795,"conditions":1796,"interventions":1799},"NCT03962686","Molecular Mechanisms and Carotid Atherosclerosis",[],"2018-01-01","2015-01-01",76,[30,1797,1798],"Atherosclerosis of Artery","Atherosclerotic Plaque",[1775],{"intervention":1801,"totalTrials":64,"cells":1802},"Lidocaine patch 5%",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1804,"activeCount":68},[],{"trials":1806,"activeCount":68},[],{"trials":1808,"activeCount":68},[],{"trials":1810,"activeCount":68},[],{"trials":1812,"activeCount":68},[],{"trials":1814,"activeCount":68},[1815],{"nctId":1816,"briefTitle":1817,"status":141,"phases":1818,"primaryCompletion":1819,"completion":1084,"start":1820,"enrollment":1085,"conditions":1821,"interventions":1823},"NCT02751619","Preventive Skin Analgesia With Lidocaine Patch 5% for Controlling Post-thoracotomy Pain",[61],"2015-05","2013-01",[1822],"Pain, Postoperative",[1801],{"intervention":1825,"totalTrials":64,"cells":1826},"SGLT-2i",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1828,"activeCount":68},[],{"trials":1830,"activeCount":68},[],{"trials":1832,"activeCount":68},[],{"trials":1834,"activeCount":68},[],{"trials":1836,"activeCount":68},[],{"trials":1838,"activeCount":68},[1839],{"nctId":1840,"briefTitle":1841,"status":141,"phases":1842,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":1846,"interventions":1847},"NCT03918148","Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)",[],"2023-12-31","2018-01-15",1150,[26],[1825,1848],"DPP-4i",{"intervention":1848,"totalTrials":64,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1852,"activeCount":68},[],{"trials":1854,"activeCount":68},[],{"trials":1856,"activeCount":68},[],{"trials":1858,"activeCount":68},[],{"trials":1860,"activeCount":68},[],{"trials":1862,"activeCount":68},[1863],{"nctId":1840,"briefTitle":1841,"status":141,"phases":1864,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":1865,"interventions":1866},[],[26],[1825,1848],{"intervention":1868,"totalTrials":64,"cells":1869},"Warfarin",{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1871,"activeCount":68},[],{"trials":1873,"activeCount":68},[],{"trials":1875,"activeCount":68},[],{"trials":1877,"activeCount":68},[],{"trials":1879,"activeCount":68},[],{"trials":1881,"activeCount":68},[1882],{"nctId":1883,"briefTitle":1884,"status":195,"phases":1885,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":1889,"conditions":1890,"interventions":1892},"NCT02069132","Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity",[],"2017-12","2018-06","2013-03",376,[18,1891],"Thrombus Due to Heart Valve Prosthesis",[1868],{"intervention":1894,"totalTrials":64,"cells":1895},"Ketamine",{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1902,"PHASE4":1904,"NA":1906},{"trials":1897,"activeCount":68},[],{"trials":1899,"activeCount":68},[],{"trials":1901,"activeCount":68},[],{"trials":1903,"activeCount":68},[],{"trials":1905,"activeCount":68},[],{"trials":1907,"activeCount":68},[1908],{"nctId":1909,"briefTitle":1910,"status":141,"phases":1911,"primaryCompletion":1912,"completion":1913,"start":1914,"enrollment":1915,"conditions":1916,"interventions":1918},"NCT03415191","The Pre-Emptive Administration Of Ketamine for Controlling Post-thoracotomy Pain",[61],"2014-12-21","2015-02-01","2012-01-05",75,[1917],"Post Thoracotomy Pain",[1894,1919],"Normal Saline",{"intervention":1919,"totalTrials":64,"cells":1921},{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1923,"activeCount":68},[],{"trials":1925,"activeCount":68},[],{"trials":1927,"activeCount":68},[],{"trials":1929,"activeCount":68},[],{"trials":1931,"activeCount":68},[],{"trials":1933,"activeCount":68},[1934],{"nctId":1909,"briefTitle":1910,"status":141,"phases":1935,"primaryCompletion":1912,"completion":1913,"start":1914,"enrollment":1915,"conditions":1936,"interventions":1937},[61],[1917],[1894,1919],{"intervention":1939,"totalTrials":64,"cells":1940},"genomicDNA extraction",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1942,"activeCount":68},[],{"trials":1944,"activeCount":68},[],{"trials":1946,"activeCount":68},[],{"trials":1948,"activeCount":68},[],{"trials":1950,"activeCount":68},[],{"trials":1952,"activeCount":68},[1953],{"nctId":1954,"briefTitle":1955,"status":195,"phases":1956,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":279,"conditions":1960,"interventions":1963},"NCT04746521","Cellular-Mediated Immunity in COVID-19",[],"2022-01-14","2022-12-14","2021-03-14",[1961,1962],"Covid19","Thromboembolism",[1939]]